SlideShare a Scribd company logo
Brendan Mulhern and Koonal Shah 
1st Meeting of the International Academy of Health Preference Research 
Amsterdam • 8 November 2014 
Does the choice of health state comparator or ordering of dimensions matter when valuing EQ-5D-5L?
IAHPR presentation 
08/11/14 2 
•This study was funded by the EuroQol Group 
•We are grateful for the contributions of Nancy Devlin, Bas Janssen, Louise Longworth and Ben van Hout 
Acknowledgements
IAHPR presentation 
08/11/14 3 
• EuroQol protocol for valuing 
EQ-5D-5L health states 
involves a combination of 
TTO and DCE tasks 
• Issue 1: In both tasks, the 
five dimensions are always 
presented in the same order 
– does the ordering matter? 
• Issue 2: In TTO, the health 
states are valued in 
comparison to “full health” – 
does the choice of 
comparator matter? 
Background: 
Valuing EQ-5D-5L 
By placing a tick in one box in each group below, please indicate which statements best 
describe your own health state TODAY. 
MOBILITY 
I have no problems in walking about  
I have slight problems in walking about  
I have moderate problems in walking about  
I have severe problems in walking about  
I am unable to walk about  
SELF-CARE 
I have no problems washing or dressing myself  
I have slight problems washing or dressing myself  
I have moderate problems washing or dressing myself  
I have severe problems washing or dressing myself  
I am unable to wash or dress myself  
USUAL ACTIVITIES (e.g. work, study, housework, 
family or leisure activities) 
I have no problems doing my usual activities  
I have slight problems doing my usual activities  
I have moderate problems doing my usual activities  
I have severe problems doing my usual activities  
I am unable to do my usual activities  
PAIN / DISCOMFORT 
I have no pain or discomfort  
I have slight pain or discomfort  
I have moderate pain or discomfort  
I have severe pain or discomfort  
I have extreme pain or discomfort  
ANXIETY / DEPRESSION 
I am not anxious or depressed  
I am slightly anxious or depressed  
I am moderately anxious or depressed  
I am severely anxious or depressed  
I am extremely anxious or depressed  
1 
1 
1 
1 
1 
11111
IAHPR presentation 
08/11/14 4 
•To assess the impact of different dimension orderings on the valuation of EQ-5D-5L health states using TTO and DCE 
•To assess differences between alternative comparator health states 
•Compare the use of “full health” and 11111 (the “best” health state defined by the EQ-5D-5L descriptive system) in TTO tasks 
•Examine respondents’ interpretations of these and other descriptors using a variety of methods 
Aims
IAHPR presentation 
08/11/14 5 
•Composite TTO used (as per EQ-5D-5L protocol) 
•‘Classic’ TTO for states better than dead (>= 0) 
•‘Lead Time’ TTO for states worse than dead (<= 0) 
•Values elicited range from -1 to 1 
Methods – TTO 
Life ALife BLife ALife BBetter than deadWorse than deadClassic TTOLEAD time TTOt=0t=10t=10t=20t=0
IAHPR presentation 
08/11/14 6 
•Pairwise comparisons of EQ-5D-5L health states 
•No indifference option offered 
Methods – DCE
IAHPR presentation 
08/11/14 7 
•3x2 design – random allocation to one of six arms 
•Two TTO comparators: 
1.Full health 
2.11111 
•Three dimension orders: 
1.Standard (MO-SC-UA-PD-AD) 
2.Reverse (AD-PD-UA-SC-MO) 
3.Block (PD-AD-MO-SC-UA) 
•10/11 TTO tasks; 7 DCE tasks 
•Follow-up questions relating to the full health vs. 11111 issue 
Methods – study design and survey administration 
•CAPI; face-to-face 
•450 general public respondents from South Yorkshire, UK
IAHPR presentation 
08/11/14 8 
•Dimension ordering – TTO 
•Comparison of descriptive statistics 
•One- and two-way ANOVA with post-hoc Bonferroni testing 
•Linear regressions (5-parameter + order; states + order) 
•Dimension ordering – DCE 
•χ2-test (examining propensity to choose one state or the other) 
•Conditional logit regressions 
•Full health vs. 11111 
•Comparison of descriptive statistics 
•t-test (examining differences in mean values across arms) 
•Analysis of self-reported health and follow-up question responses 
Methods of analysis
IAHPR presentation 
08/11/14 9 
Results – TTO 
Model 1: 5 para 
Model 5: State 
Coef. 
Sig. 
Coef. 
Sig 
MO 
-0.002 
0.87 
SC 
-0.105 
0.00 
UA 
-0.061 
0.00 
PD 
-0.073 
0.00 
AD 
-0.059 
0.00 
State 
11112 
-0.036 
0.20 
11121 
-0.019 
0.51 
11223 
-0.166 
0.00 
21111 
-0.025 
0.37 
21232 
-0.175 
0.00 
32442 
-0.603 
0.00 
34155 
-0.833 
0.00 
43331 
-0.403 
0.00 
55233 
-0.706 
0.00 
55555 
-1.171 
0.00 
Order 
0.029 
0.06 
0.029 
0.06 
Gender 
0.034 
0.19 
0.034 
0.19 
Age 
-0.001 
0.09 
-0.001 
0.09 
N 
442 
442 
Wald 
5615 
5765 
State 
Standard 
MO-SC-UA-PD-AD (n=146) 
Reverse 
AD-PD-UA-SC-MO (n=149) 
Block 
PD-AD-MO-SC-UA (n=147) 
M(sd) 
Range 
M(sd) 
Range 
M(sd) 
Range 
Overall 
Overall 
0.554 (0.60) 
-1 to 1 
0.610 (0.55) 
-1 to 1 
0.610 (0.54) 
-1 to 1 
0.01 
11111 
1.000 (0.00) 
1 to 1 
0.998 (0.01) 
0.9 to 1 
0.999 (0.01) 
0.95 to 1 
0.36 
21111 
0.949 (0.14) 
0.05 to 1 
0.961 (0.11) 
0.2 to 1 
0.968 (0.10) 
0 to 1 
0.38 
11121 
0.968 (0.09) 
0.5 to 1 
0.967 (0.10) 
0.2 to 1 
0.963 (0.10) 
0.1 to 1 
0.90 
11112 
0.941 (0.20) 
-1 to 1 
0.956 (0.12) 
0 to 1 
0.948 (0.13) 
0 to 1 
0.71 
11223 
0.757(0.43) 
-1 to 1 
0.848 (0.26) 
-1 to 1 
0.849 (0.19) 
0.3 to 1 
0.02 
21232 
0.754(0.38) 
-1 to 1 
0.838 (0.24) 
-0.45 to 1 
0.837 (0.20) 
0 to 1 
0.01 
43331 
0.516 (0.55) 
-1 to 1 
0.590 (0.52) 
-1 to 1 
0.637 (0.35) 
-1 to 1 
0.10 
32442 
0.323 (0.59) 
-1 to 1 
0.418 (0.54) 
-1 to 1 
0.404 (0.54) 
-1 to 1 
0.28 
55233 
0.238 (0.62) 
-1 to 1 
0.310 (0.61) 
-1 to 1 
0.287 (0.60) 
-1 to 1 
0.59 
34155 
0.129 (0.62) 
-1 to 1 
0.163 (0.63) 
-1 to 1 
0.160 (0.61) 
-1 to 1 
0.87 
55555 
-0.260 (0.5) 
-1 to 0.95 
-0.144 (0.54) 
-1 to 1 
-0.155 (0.58) 
-1 to 1 
0.15 
Descriptive analysis 
Regression analysis
IAHPR presentation 
08/11/14 10 
Results – DCE 
Descriptive analysis 
Regression analysis 
MO-SC-UA-PD-AD 
AD-PD-UA-SC-MO 
PD-AD-MO-SC-UA 
Coef. 
Sig. 
Order 
Coef. 
Sig. 
Order 
Coef. 
Sig. 
Order 
MO 
-0.198 
0.05 
4 
-0.264 
0.09 
2 
-0.282 
0.05 
4 
SC 
-0.281 
0.04 
3 
-0.260 
0.05 
3 
-0.410 
0.00 
2 
UA 
-0.313 
0.00 
2 
-0.240 
0.00 
4 
-0.227 
0.00 
5 
PD 
-0.142 
0.28 
5 
-0.204 
0.11 
5 
-0.394 
0.03 
3 
AD 
-0.367 
0.00 
1 
-0.404 
0.00 
1 
-0.525 
0.00 
1 
n 
2100 
2170 
2100 
LL 
-683 
-710 
-674 
0% 
20% 
40% 
60% 
80% 
100% 
31113 (state 1) /11331 (state 2) 
44222 (state 1) / 22244 (state 2) 
% choosing state 1 
Standard 
Reverse 
Block
IAHPR presentation 
08/11/14 11 
•No statistically significant differences were observed across the arms in terms of mean values (t-test; p=0.10) or other key measures of data quality (e.g. inconsistencies) 
•Four respondents (1.8%) gave 11111 a value other than 1 (mean=0.999) 
•However, of the 224 respondents who self-reported as being in 11111, only 37 (16.5%) rated themselves as 100 on a 0- 100 scale where 100 = “best imaginable health” 
•Mean (median) rating for respondents self-reporting as being in 11111 was 89 (90) 
Full health vs. 11111
IAHPR presentation 
08/11/14 12 
•Q: Do you consider these descriptions [full health and 11111] to be the same as each other? 
•29.9% of respondents answered NO 
•Q: Please rate the descriptions on a 0-100 scale where 0 = worst imaginable health and 100 = best imaginable health 
•Mean rating for full health = 98.6; 86.0% gave it a rating of 100 
•Mean rating for 11111 = 95.1; 58.2% gave it a rating of 100 
•Q: Which of these descriptions [perfect health; full health; best imaginable health; no health problems; 11111; healthy] would you most want to live in? 
•Perfect health most often ranked best or joint best 
•344 respondents (79.1%) did not rank 11111 as best or joint best 
Full health vs. 11111 – follow-up questions
IAHPR presentation 
08/11/14 13 
•Dimension ordering seems to affect TTO values (standard vs. non-standard)… 
•…but the effects of order do not appear to be systematic or easily explainable 
•Randomisation of dimension ordering between respondents seems like a no-brainer 
•Are there other hypotheses that we should have explored? Should we have designed or analysed the study differently? 
•Should past studies have used randomised ordering? 
•Any other suggestions for exploring the differences between full health and 11111? Are there benefits for using one anchor or the other? 
Some discussion points
IAHPR presentation 
08/11/14 14 
Thank you for listening kshah@ohe.org

More Related Content

Similar to Ispor choice health-state-comparator-matter_eq_5_d_5l-kks_nov2014

A New Approach to Presenting Health States in Stated Preference Valuation Stu...
A New Approach to Presenting Health States in Stated Preference Valuation Stu...A New Approach to Presenting Health States in Stated Preference Valuation Stu...
A New Approach to Presenting Health States in Stated Preference Valuation Stu...
Office of Health Economics
 
Where's WALY - Aileen Clarke and Sian Taylor-Phillips
Where's WALY - Aileen Clarke and Sian Taylor-PhillipsWhere's WALY - Aileen Clarke and Sian Taylor-Phillips
Where's WALY - Aileen Clarke and Sian Taylor-Phillips
NIHR CLAHRC West Midlands
 
Nursing-2009-Hays-July 20-HRQOL (1).ppt
Nursing-2009-Hays-July 20-HRQOL (1).pptNursing-2009-Hays-July 20-HRQOL (1).ppt
Nursing-2009-Hays-July 20-HRQOL (1).ppt
AlexandruBuruc
 
9. van anh vđ english
9. van anh vđ english9. van anh vđ english
9. van anh vđ english
vinhvd12
 
Age, utilities, and self-reported health: issues for HTA
Age, utilities, and self-reported health: issues for HTAAge, utilities, and self-reported health: issues for HTA
Age, utilities, and self-reported health: issues for HTA
Office of Health Economics
 
Cadth 2015 e3 eq5 d
Cadth 2015 e3  eq5 dCadth 2015 e3  eq5 d
Cadth 2015 e3 eq5 d
CADTH Symposium
 
Comparative hospital performance: new data, borrowed methods, more targeted a...
Comparative hospital performance: new data, borrowed methods, more targeted a...Comparative hospital performance: new data, borrowed methods, more targeted a...
Comparative hospital performance: new data, borrowed methods, more targeted a...
cheweb1
 
Robust Methods for Health-related Quality-of-life Assessment
Robust Methods for Health-related Quality-of-life AssessmentRobust Methods for Health-related Quality-of-life Assessment
Robust Methods for Health-related Quality-of-life Assessment
dylanturner22
 
A Comparison of Three EQ-5D Value sets
A Comparison of Three EQ-5D Value setsA Comparison of Three EQ-5D Value sets
A Comparison of Three EQ-5D Value sets
Office of Health Economics
 
Anchoring Vignettes: Identifying response bias and DIF in self assessed health
Anchoring Vignettes: Identifying response bias and DIF in self assessed healthAnchoring Vignettes: Identifying response bias and DIF in self assessed health
Anchoring Vignettes: Identifying response bias and DIF in self assessed health
Office of Health Economics
 
Using TTO and DCE in the UAE to Determine Health State Preferences
Using TTO and DCE in the UAE to Determine Health State PreferencesUsing TTO and DCE in the UAE to Determine Health State Preferences
Using TTO and DCE in the UAE to Determine Health State Preferences
Office of Health Economics
 
Does the physical work capacity of subjects with early osteoarthritis of hip ...
Does the physical work capacity of subjects with early osteoarthritis of hip ...Does the physical work capacity of subjects with early osteoarthritis of hip ...
Does the physical work capacity of subjects with early osteoarthritis of hip ...
SaxionZorgWelzijn
 
Health state utilities of periodontitis patients
Health state utilities of periodontitis patients Health state utilities of periodontitis patients
Health state utilities of periodontitis patients
UKM
 
Application of EQ-5D in Reimbursement Decision Making: The Case of NICE
Application of EQ-5D in Reimbursement Decision Making: The Case of NICEApplication of EQ-5D in Reimbursement Decision Making: The Case of NICE
Application of EQ-5D in Reimbursement Decision Making: The Case of NICE
Office of Health Economics
 
CSM 2017 Stout
CSM 2017 StoutCSM 2017 Stout
CSM 2017 Stout
Dr. Chris Stout
 
Ct lecture 4. descriptive analysis of cont variables
Ct lecture 4. descriptive analysis of cont variablesCt lecture 4. descriptive analysis of cont variables
Ct lecture 4. descriptive analysis of cont variables
Hau Pham
 
Robust Methods for Health-related Quality-of-life Assessment
Robust Methods for Health-related  Quality-of-life AssessmentRobust Methods for Health-related  Quality-of-life Assessment
Robust Methods for Health-related Quality-of-life Assessment
dylanturner22
 
1000 Minds Poster
1000 Minds Poster1000 Minds Poster
1000 Minds Poster
Amy Livingstone
 
Ct lecture 7. comparing two groups cont data
Ct lecture 7. comparing two groups   cont dataCt lecture 7. comparing two groups   cont data
Ct lecture 7. comparing two groups cont data
Hau Pham
 
Cadth 2015 a4 2015 cadth values
Cadth 2015 a4 2015 cadth valuesCadth 2015 a4 2015 cadth values
Cadth 2015 a4 2015 cadth values
CADTH Symposium
 

Similar to Ispor choice health-state-comparator-matter_eq_5_d_5l-kks_nov2014 (20)

A New Approach to Presenting Health States in Stated Preference Valuation Stu...
A New Approach to Presenting Health States in Stated Preference Valuation Stu...A New Approach to Presenting Health States in Stated Preference Valuation Stu...
A New Approach to Presenting Health States in Stated Preference Valuation Stu...
 
Where's WALY - Aileen Clarke and Sian Taylor-Phillips
Where's WALY - Aileen Clarke and Sian Taylor-PhillipsWhere's WALY - Aileen Clarke and Sian Taylor-Phillips
Where's WALY - Aileen Clarke and Sian Taylor-Phillips
 
Nursing-2009-Hays-July 20-HRQOL (1).ppt
Nursing-2009-Hays-July 20-HRQOL (1).pptNursing-2009-Hays-July 20-HRQOL (1).ppt
Nursing-2009-Hays-July 20-HRQOL (1).ppt
 
9. van anh vđ english
9. van anh vđ english9. van anh vđ english
9. van anh vđ english
 
Age, utilities, and self-reported health: issues for HTA
Age, utilities, and self-reported health: issues for HTAAge, utilities, and self-reported health: issues for HTA
Age, utilities, and self-reported health: issues for HTA
 
Cadth 2015 e3 eq5 d
Cadth 2015 e3  eq5 dCadth 2015 e3  eq5 d
Cadth 2015 e3 eq5 d
 
Comparative hospital performance: new data, borrowed methods, more targeted a...
Comparative hospital performance: new data, borrowed methods, more targeted a...Comparative hospital performance: new data, borrowed methods, more targeted a...
Comparative hospital performance: new data, borrowed methods, more targeted a...
 
Robust Methods for Health-related Quality-of-life Assessment
Robust Methods for Health-related Quality-of-life AssessmentRobust Methods for Health-related Quality-of-life Assessment
Robust Methods for Health-related Quality-of-life Assessment
 
A Comparison of Three EQ-5D Value sets
A Comparison of Three EQ-5D Value setsA Comparison of Three EQ-5D Value sets
A Comparison of Three EQ-5D Value sets
 
Anchoring Vignettes: Identifying response bias and DIF in self assessed health
Anchoring Vignettes: Identifying response bias and DIF in self assessed healthAnchoring Vignettes: Identifying response bias and DIF in self assessed health
Anchoring Vignettes: Identifying response bias and DIF in self assessed health
 
Using TTO and DCE in the UAE to Determine Health State Preferences
Using TTO and DCE in the UAE to Determine Health State PreferencesUsing TTO and DCE in the UAE to Determine Health State Preferences
Using TTO and DCE in the UAE to Determine Health State Preferences
 
Does the physical work capacity of subjects with early osteoarthritis of hip ...
Does the physical work capacity of subjects with early osteoarthritis of hip ...Does the physical work capacity of subjects with early osteoarthritis of hip ...
Does the physical work capacity of subjects with early osteoarthritis of hip ...
 
Health state utilities of periodontitis patients
Health state utilities of periodontitis patients Health state utilities of periodontitis patients
Health state utilities of periodontitis patients
 
Application of EQ-5D in Reimbursement Decision Making: The Case of NICE
Application of EQ-5D in Reimbursement Decision Making: The Case of NICEApplication of EQ-5D in Reimbursement Decision Making: The Case of NICE
Application of EQ-5D in Reimbursement Decision Making: The Case of NICE
 
CSM 2017 Stout
CSM 2017 StoutCSM 2017 Stout
CSM 2017 Stout
 
Ct lecture 4. descriptive analysis of cont variables
Ct lecture 4. descriptive analysis of cont variablesCt lecture 4. descriptive analysis of cont variables
Ct lecture 4. descriptive analysis of cont variables
 
Robust Methods for Health-related Quality-of-life Assessment
Robust Methods for Health-related  Quality-of-life AssessmentRobust Methods for Health-related  Quality-of-life Assessment
Robust Methods for Health-related Quality-of-life Assessment
 
1000 Minds Poster
1000 Minds Poster1000 Minds Poster
1000 Minds Poster
 
Ct lecture 7. comparing two groups cont data
Ct lecture 7. comparing two groups   cont dataCt lecture 7. comparing two groups   cont data
Ct lecture 7. comparing two groups cont data
 
Cadth 2015 a4 2015 cadth values
Cadth 2015 a4 2015 cadth valuesCadth 2015 a4 2015 cadth values
Cadth 2015 a4 2015 cadth values
 

More from Office of Health Economics

Annual lecture
Annual lecture Annual lecture
Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20 Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20
Office of Health Economics
 
Towse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne finalTowse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne final
Office of Health Economics
 
Towse cgd price transparency seminar
Towse cgd price transparency seminarTowse cgd price transparency seminar
Towse cgd price transparency seminar
Office of Health Economics
 
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
Office of Health Economics
 
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowsePricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian Towse
Office of Health Economics
 
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
Office of Health Economics
 
The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...
Office of Health Economics
 
ISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money is
Office of Health Economics
 
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Office of Health Economics
 
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY? IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
Office of Health Economics
 
Ispor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-MollaIspor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-Molla
Office of Health Economics
 
Understanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleUnderstanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to people
Office of Health Economics
 
Novel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeNovel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of life
Office of Health Economics
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Office of Health Economics
 
HTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMRHTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMR
Office of Health Economics
 
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Office of Health Economics
 
Pay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandPay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in England
Office of Health Economics
 
Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Real option value drugs: is it really an option?
Real option value drugs: is it really an option?
Office of Health Economics
 
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
Office of Health Economics
 

More from Office of Health Economics (20)

Annual lecture
Annual lecture Annual lecture
Annual lecture
 
Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20 Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20
 
Towse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne finalTowse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne final
 
Towse cgd price transparency seminar
Towse cgd price transparency seminarTowse cgd price transparency seminar
Towse cgd price transparency seminar
 
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
 
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowsePricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian Towse
 
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
 
The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...
 
ISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money is
 
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
 
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY? IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 
Ispor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-MollaIspor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-Molla
 
Understanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleUnderstanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to people
 
Novel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeNovel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of life
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
 
HTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMRHTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMR
 
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
 
Pay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandPay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in England
 
Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Real option value drugs: is it really an option?
Real option value drugs: is it really an option?
 
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
 

Recently uploaded

2024-05-30_meetup_devops_aix-marseille.pdf
2024-05-30_meetup_devops_aix-marseille.pdf2024-05-30_meetup_devops_aix-marseille.pdf
2024-05-30_meetup_devops_aix-marseille.pdf
Frederic Leger
 
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij
 
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Competition and Regulation in Professions and Occupations – ROBSON – June 202...Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
OECD Directorate for Financial and Enterprise Affairs
 
International Workshop on Artificial Intelligence in Software Testing
International Workshop on Artificial Intelligence in Software TestingInternational Workshop on Artificial Intelligence in Software Testing
International Workshop on Artificial Intelligence in Software Testing
Sebastiano Panichella
 
Announcement of 18th IEEE International Conference on Software Testing, Verif...
Announcement of 18th IEEE International Conference on Software Testing, Verif...Announcement of 18th IEEE International Conference on Software Testing, Verif...
Announcement of 18th IEEE International Conference on Software Testing, Verif...
Sebastiano Panichella
 
ASONAM2023_presection_slide_track-recommendation.pdf
ASONAM2023_presection_slide_track-recommendation.pdfASONAM2023_presection_slide_track-recommendation.pdf
ASONAM2023_presection_slide_track-recommendation.pdf
ToshihiroIto4
 
Burning Issue Presentation By Kenmaryon.pdf
Burning Issue Presentation By Kenmaryon.pdfBurning Issue Presentation By Kenmaryon.pdf
Burning Issue Presentation By Kenmaryon.pdf
kkirkland2
 
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdfSupercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
Access Innovations, Inc.
 
Media as a Mind Controlling Strategy In Old and Modern Era
Media as a Mind Controlling Strategy In Old and Modern EraMedia as a Mind Controlling Strategy In Old and Modern Era
Media as a Mind Controlling Strategy In Old and Modern Era
faizulhassanfaiz1670
 
Gregory Harris - Cycle 2 - Civics Presentation
Gregory Harris - Cycle 2 - Civics PresentationGregory Harris - Cycle 2 - Civics Presentation
Gregory Harris - Cycle 2 - Civics Presentation
gharris9
 
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
OECD Directorate for Financial and Enterprise Affairs
 
Doctoral Symposium at the 17th IEEE International Conference on Software Test...
Doctoral Symposium at the 17th IEEE International Conference on Software Test...Doctoral Symposium at the 17th IEEE International Conference on Software Test...
Doctoral Symposium at the 17th IEEE International Conference on Software Test...
Sebastiano Panichella
 
Bonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdf
Bonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdfBonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdf
Bonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdf
khadija278284
 
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie WellsCollapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Rosie Wells
 
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Dutch Power
 
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Dutch Power
 
María Carolina Martínez - eCommerce Day Colombia 2024
María Carolina Martínez - eCommerce Day Colombia 2024María Carolina Martínez - eCommerce Day Colombia 2024
María Carolina Martínez - eCommerce Day Colombia 2024
eCommerce Institute
 
Tom tresser burning issue.pptx My Burning issue
Tom tresser burning issue.pptx My Burning issueTom tresser burning issue.pptx My Burning issue
Tom tresser burning issue.pptx My Burning issue
amekonnen
 
XP 2024 presentation: A New Look to Leadership
XP 2024 presentation: A New Look to LeadershipXP 2024 presentation: A New Look to Leadership
XP 2024 presentation: A New Look to Leadership
samililja
 
Updated diagnosis. Cause and treatment of hypothyroidism
Updated diagnosis. Cause and treatment of hypothyroidismUpdated diagnosis. Cause and treatment of hypothyroidism
Updated diagnosis. Cause and treatment of hypothyroidism
Faculty of Medicine And Health Sciences
 

Recently uploaded (20)

2024-05-30_meetup_devops_aix-marseille.pdf
2024-05-30_meetup_devops_aix-marseille.pdf2024-05-30_meetup_devops_aix-marseille.pdf
2024-05-30_meetup_devops_aix-marseille.pdf
 
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
 
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Competition and Regulation in Professions and Occupations – ROBSON – June 202...Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
 
International Workshop on Artificial Intelligence in Software Testing
International Workshop on Artificial Intelligence in Software TestingInternational Workshop on Artificial Intelligence in Software Testing
International Workshop on Artificial Intelligence in Software Testing
 
Announcement of 18th IEEE International Conference on Software Testing, Verif...
Announcement of 18th IEEE International Conference on Software Testing, Verif...Announcement of 18th IEEE International Conference on Software Testing, Verif...
Announcement of 18th IEEE International Conference on Software Testing, Verif...
 
ASONAM2023_presection_slide_track-recommendation.pdf
ASONAM2023_presection_slide_track-recommendation.pdfASONAM2023_presection_slide_track-recommendation.pdf
ASONAM2023_presection_slide_track-recommendation.pdf
 
Burning Issue Presentation By Kenmaryon.pdf
Burning Issue Presentation By Kenmaryon.pdfBurning Issue Presentation By Kenmaryon.pdf
Burning Issue Presentation By Kenmaryon.pdf
 
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdfSupercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
 
Media as a Mind Controlling Strategy In Old and Modern Era
Media as a Mind Controlling Strategy In Old and Modern EraMedia as a Mind Controlling Strategy In Old and Modern Era
Media as a Mind Controlling Strategy In Old and Modern Era
 
Gregory Harris - Cycle 2 - Civics Presentation
Gregory Harris - Cycle 2 - Civics PresentationGregory Harris - Cycle 2 - Civics Presentation
Gregory Harris - Cycle 2 - Civics Presentation
 
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
 
Doctoral Symposium at the 17th IEEE International Conference on Software Test...
Doctoral Symposium at the 17th IEEE International Conference on Software Test...Doctoral Symposium at the 17th IEEE International Conference on Software Test...
Doctoral Symposium at the 17th IEEE International Conference on Software Test...
 
Bonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdf
Bonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdfBonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdf
Bonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdf
 
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie WellsCollapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
 
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
 
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
 
María Carolina Martínez - eCommerce Day Colombia 2024
María Carolina Martínez - eCommerce Day Colombia 2024María Carolina Martínez - eCommerce Day Colombia 2024
María Carolina Martínez - eCommerce Day Colombia 2024
 
Tom tresser burning issue.pptx My Burning issue
Tom tresser burning issue.pptx My Burning issueTom tresser burning issue.pptx My Burning issue
Tom tresser burning issue.pptx My Burning issue
 
XP 2024 presentation: A New Look to Leadership
XP 2024 presentation: A New Look to LeadershipXP 2024 presentation: A New Look to Leadership
XP 2024 presentation: A New Look to Leadership
 
Updated diagnosis. Cause and treatment of hypothyroidism
Updated diagnosis. Cause and treatment of hypothyroidismUpdated diagnosis. Cause and treatment of hypothyroidism
Updated diagnosis. Cause and treatment of hypothyroidism
 

Ispor choice health-state-comparator-matter_eq_5_d_5l-kks_nov2014

  • 1. Brendan Mulhern and Koonal Shah 1st Meeting of the International Academy of Health Preference Research Amsterdam • 8 November 2014 Does the choice of health state comparator or ordering of dimensions matter when valuing EQ-5D-5L?
  • 2. IAHPR presentation 08/11/14 2 •This study was funded by the EuroQol Group •We are grateful for the contributions of Nancy Devlin, Bas Janssen, Louise Longworth and Ben van Hout Acknowledgements
  • 3. IAHPR presentation 08/11/14 3 • EuroQol protocol for valuing EQ-5D-5L health states involves a combination of TTO and DCE tasks • Issue 1: In both tasks, the five dimensions are always presented in the same order – does the ordering matter? • Issue 2: In TTO, the health states are valued in comparison to “full health” – does the choice of comparator matter? Background: Valuing EQ-5D-5L By placing a tick in one box in each group below, please indicate which statements best describe your own health state TODAY. MOBILITY I have no problems in walking about  I have slight problems in walking about  I have moderate problems in walking about  I have severe problems in walking about  I am unable to walk about  SELF-CARE I have no problems washing or dressing myself  I have slight problems washing or dressing myself  I have moderate problems washing or dressing myself  I have severe problems washing or dressing myself  I am unable to wash or dress myself  USUAL ACTIVITIES (e.g. work, study, housework, family or leisure activities) I have no problems doing my usual activities  I have slight problems doing my usual activities  I have moderate problems doing my usual activities  I have severe problems doing my usual activities  I am unable to do my usual activities  PAIN / DISCOMFORT I have no pain or discomfort  I have slight pain or discomfort  I have moderate pain or discomfort  I have severe pain or discomfort  I have extreme pain or discomfort  ANXIETY / DEPRESSION I am not anxious or depressed  I am slightly anxious or depressed  I am moderately anxious or depressed  I am severely anxious or depressed  I am extremely anxious or depressed  1 1 1 1 1 11111
  • 4. IAHPR presentation 08/11/14 4 •To assess the impact of different dimension orderings on the valuation of EQ-5D-5L health states using TTO and DCE •To assess differences between alternative comparator health states •Compare the use of “full health” and 11111 (the “best” health state defined by the EQ-5D-5L descriptive system) in TTO tasks •Examine respondents’ interpretations of these and other descriptors using a variety of methods Aims
  • 5. IAHPR presentation 08/11/14 5 •Composite TTO used (as per EQ-5D-5L protocol) •‘Classic’ TTO for states better than dead (>= 0) •‘Lead Time’ TTO for states worse than dead (<= 0) •Values elicited range from -1 to 1 Methods – TTO Life ALife BLife ALife BBetter than deadWorse than deadClassic TTOLEAD time TTOt=0t=10t=10t=20t=0
  • 6. IAHPR presentation 08/11/14 6 •Pairwise comparisons of EQ-5D-5L health states •No indifference option offered Methods – DCE
  • 7. IAHPR presentation 08/11/14 7 •3x2 design – random allocation to one of six arms •Two TTO comparators: 1.Full health 2.11111 •Three dimension orders: 1.Standard (MO-SC-UA-PD-AD) 2.Reverse (AD-PD-UA-SC-MO) 3.Block (PD-AD-MO-SC-UA) •10/11 TTO tasks; 7 DCE tasks •Follow-up questions relating to the full health vs. 11111 issue Methods – study design and survey administration •CAPI; face-to-face •450 general public respondents from South Yorkshire, UK
  • 8. IAHPR presentation 08/11/14 8 •Dimension ordering – TTO •Comparison of descriptive statistics •One- and two-way ANOVA with post-hoc Bonferroni testing •Linear regressions (5-parameter + order; states + order) •Dimension ordering – DCE •χ2-test (examining propensity to choose one state or the other) •Conditional logit regressions •Full health vs. 11111 •Comparison of descriptive statistics •t-test (examining differences in mean values across arms) •Analysis of self-reported health and follow-up question responses Methods of analysis
  • 9. IAHPR presentation 08/11/14 9 Results – TTO Model 1: 5 para Model 5: State Coef. Sig. Coef. Sig MO -0.002 0.87 SC -0.105 0.00 UA -0.061 0.00 PD -0.073 0.00 AD -0.059 0.00 State 11112 -0.036 0.20 11121 -0.019 0.51 11223 -0.166 0.00 21111 -0.025 0.37 21232 -0.175 0.00 32442 -0.603 0.00 34155 -0.833 0.00 43331 -0.403 0.00 55233 -0.706 0.00 55555 -1.171 0.00 Order 0.029 0.06 0.029 0.06 Gender 0.034 0.19 0.034 0.19 Age -0.001 0.09 -0.001 0.09 N 442 442 Wald 5615 5765 State Standard MO-SC-UA-PD-AD (n=146) Reverse AD-PD-UA-SC-MO (n=149) Block PD-AD-MO-SC-UA (n=147) M(sd) Range M(sd) Range M(sd) Range Overall Overall 0.554 (0.60) -1 to 1 0.610 (0.55) -1 to 1 0.610 (0.54) -1 to 1 0.01 11111 1.000 (0.00) 1 to 1 0.998 (0.01) 0.9 to 1 0.999 (0.01) 0.95 to 1 0.36 21111 0.949 (0.14) 0.05 to 1 0.961 (0.11) 0.2 to 1 0.968 (0.10) 0 to 1 0.38 11121 0.968 (0.09) 0.5 to 1 0.967 (0.10) 0.2 to 1 0.963 (0.10) 0.1 to 1 0.90 11112 0.941 (0.20) -1 to 1 0.956 (0.12) 0 to 1 0.948 (0.13) 0 to 1 0.71 11223 0.757(0.43) -1 to 1 0.848 (0.26) -1 to 1 0.849 (0.19) 0.3 to 1 0.02 21232 0.754(0.38) -1 to 1 0.838 (0.24) -0.45 to 1 0.837 (0.20) 0 to 1 0.01 43331 0.516 (0.55) -1 to 1 0.590 (0.52) -1 to 1 0.637 (0.35) -1 to 1 0.10 32442 0.323 (0.59) -1 to 1 0.418 (0.54) -1 to 1 0.404 (0.54) -1 to 1 0.28 55233 0.238 (0.62) -1 to 1 0.310 (0.61) -1 to 1 0.287 (0.60) -1 to 1 0.59 34155 0.129 (0.62) -1 to 1 0.163 (0.63) -1 to 1 0.160 (0.61) -1 to 1 0.87 55555 -0.260 (0.5) -1 to 0.95 -0.144 (0.54) -1 to 1 -0.155 (0.58) -1 to 1 0.15 Descriptive analysis Regression analysis
  • 10. IAHPR presentation 08/11/14 10 Results – DCE Descriptive analysis Regression analysis MO-SC-UA-PD-AD AD-PD-UA-SC-MO PD-AD-MO-SC-UA Coef. Sig. Order Coef. Sig. Order Coef. Sig. Order MO -0.198 0.05 4 -0.264 0.09 2 -0.282 0.05 4 SC -0.281 0.04 3 -0.260 0.05 3 -0.410 0.00 2 UA -0.313 0.00 2 -0.240 0.00 4 -0.227 0.00 5 PD -0.142 0.28 5 -0.204 0.11 5 -0.394 0.03 3 AD -0.367 0.00 1 -0.404 0.00 1 -0.525 0.00 1 n 2100 2170 2100 LL -683 -710 -674 0% 20% 40% 60% 80% 100% 31113 (state 1) /11331 (state 2) 44222 (state 1) / 22244 (state 2) % choosing state 1 Standard Reverse Block
  • 11. IAHPR presentation 08/11/14 11 •No statistically significant differences were observed across the arms in terms of mean values (t-test; p=0.10) or other key measures of data quality (e.g. inconsistencies) •Four respondents (1.8%) gave 11111 a value other than 1 (mean=0.999) •However, of the 224 respondents who self-reported as being in 11111, only 37 (16.5%) rated themselves as 100 on a 0- 100 scale where 100 = “best imaginable health” •Mean (median) rating for respondents self-reporting as being in 11111 was 89 (90) Full health vs. 11111
  • 12. IAHPR presentation 08/11/14 12 •Q: Do you consider these descriptions [full health and 11111] to be the same as each other? •29.9% of respondents answered NO •Q: Please rate the descriptions on a 0-100 scale where 0 = worst imaginable health and 100 = best imaginable health •Mean rating for full health = 98.6; 86.0% gave it a rating of 100 •Mean rating for 11111 = 95.1; 58.2% gave it a rating of 100 •Q: Which of these descriptions [perfect health; full health; best imaginable health; no health problems; 11111; healthy] would you most want to live in? •Perfect health most often ranked best or joint best •344 respondents (79.1%) did not rank 11111 as best or joint best Full health vs. 11111 – follow-up questions
  • 13. IAHPR presentation 08/11/14 13 •Dimension ordering seems to affect TTO values (standard vs. non-standard)… •…but the effects of order do not appear to be systematic or easily explainable •Randomisation of dimension ordering between respondents seems like a no-brainer •Are there other hypotheses that we should have explored? Should we have designed or analysed the study differently? •Should past studies have used randomised ordering? •Any other suggestions for exploring the differences between full health and 11111? Are there benefits for using one anchor or the other? Some discussion points
  • 14. IAHPR presentation 08/11/14 14 Thank you for listening kshah@ohe.org